Delivery Order SPE2DR25D2001-SPE2DR26FBGN0
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $108,228.44 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on January 12, 2026, with an ultimate completion date of January 13, 2026. This firm fixed-price, non-set-aside contract is performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $4,724.33 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on January 12, 2026, with an ultimate completion date of January 13, 2026. This is a firm fixed-price, non-set-aside contract performed at the contractor's headquarters in Conshohocken, Pennsylvania. The award represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets in a quantity of 30 units, with a ceiling value of $87,792.14. This firm fixed-price delivery order, awarded on July 23, 2025, represents a non-set-aside competitive award with an ultimate completion date of July 24, 2025. The pharmaceutical products will be delivered to the company's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office and...
- The Defense Logistics Agency awarded a $13,061.94 firm fixed-price delivery order to AmerisourceBergen Drug Corp on January 8, 2026, for RINVOQ ER 15 mg tablets (30-count units), with final delivery due January 9, 2026. This non-set-aside award was competitively procured and is being performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The order represents a task order execution under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $10,807.47 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on January 8, 2026, with an ultimate completion date of January 9, 2026. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc., is a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $6,762.36 to AmerisourceBergen Drug Corp for the supply of RINVOQ ER 15 mg tablets (30-count units) on January 13, 2026, with an ultimate completion date of January 14, 2026. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract represents a single task order under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $17,740.56 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on January 9, 2026, with a completion date of January 12, 2026. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The award is issued under AmerisourceBergen's parent company Cencora, Inc.'s Indefinite Delivery Contract with DLA Troop Support Medical, a comprehensive pharmaceutical supply vehicle valued at...
- The Defense Logistics Agency awarded a delivery order valued at $3,279.20 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose packaging) on January 13, 2026, with a completion date of January 14, 2026. This non-set-aside, competitively awarded contract was issued as a firm fixed-price delivery order and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major...
- The Defense Logistics Agency awarded a delivery order valued at $13,116.80 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on January 6, 2026, with an ultimate completion date of January 7, 2026. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $5,846.07 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on August 21, 2025, with a completion date of August 22, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, to be performed at the contractor's Conshohocken, Pennsylvania location. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- SPE2DR25D2001Indefinite Delivery Contract
- SPE2DR25D2001-SPE2DR26FBGN0Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $13.5 million to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on January 20, 2026, with completion scheduled for January 21, 2026. This firm fixed-price contract, which carries no set-aside designation, will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The award represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999 through December 31, 2031, which serves as the primary vehicle for supplying pharmaceutical products and medical supplies to military healthcare systems globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, was selected through full and open competition to fulfill this medical supply requirement. RINVOQ (upadacitinib) is a Janus kinase inhibitor used in the treatment of rheumatoid arthritis and other inflammatory conditions, reflecting the breadth of therapeutic medications supplied through the DLA Troop Support Medical contract vehicle. This delivery order demonstrates the company's critical role in supporting Defense Health Agency operations and military treatment facilities worldwide through efficient fulfillment of essential pharmaceutical commodities required by federal medical institutions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.5k | 1/19/26 |